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Abstract 
This study has been designed to confirm the protective effect of different single oral doses 
of L-arginine in the presence of equimolar doses of ibuprofen, and to compare the results 
with those obtained after treatment with ibuprofen alone. Different parameters were 
assessed in rats: gastric damage (mm2 and score), ratio of lesionated stomachs/total 
stomachs evaluated, and presence of haemorrhage. 
Six hours after dosing, oral administration of ibuprofen (0.3, 0.6 and 1.2 mmol kg-') 
produced a progressive dose-dependent increase in damage to the gastric mucosa. All 
treatments with equimolar doses of L-arginine considerably reduced lesions (mm2 and 
score) and the same tendency was observed with the other parameters examined. We also 
evaluated the gastroprotective effect of L-arginine against anti-ulcer reference drugs, 
ranitidine and roxatidine (two antisecretory agents) and misoprostol (a cytoprotective 
drug). The degree of inhibition of damage provided by L-arginine was similar to those 
obtained with the other drugs. 
Thus, we conclude that the simultaneous administration of equimolar doses of ibuprofen 
and L-arginine offers significant protection compared with gastrolesive doses of ibuprofen 
alone, with an important decrease in the lesionated areas and improvement of the vascular 
state. The extent of this protective action is comparable with that observed with anti-ulcer 
reference drugs. 
Non-steroidal anti-inflammatory drugs (NSAIDs) 
are among the most commonly used drugs in the 
world, but their use in the treatment of pain, fever 
and inflammation, and in particular, in the treat- 
ment of arthritis, is associated with significant 
untoward effects on the gastrointestinal tract. The 
bleeding and ulceration induced in the stomach by 
NSAIDs is the most common adverse reaction to 
medication and has a significant financial impact on 
health care. Their gastric toxicity is related to 
suppression of prostaglandin synthesis, through 
inhibition of cyclooxygenase activity, and in addi- 
tion, several NSAIDs have topical irritant proper- 
ties on gastric mucosa. 
In the last few years, a number of different stra- 
tegies for developing NSAlDs with reduced gastric 
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toxicity have been used. These include formulating 
the agents with an enteric coating to prevent 
absorption in the stomach, the development of pro- 
drugs, which are not active until they have under- 
gone metabolism by the liver, and co-administra- 
tion of either suppressors of acid (anti-H2 or proton 
pump inhibitors) or exogenous prostaglandins. 
Recently, a new strategy related to the role of 
nitric oxide (NO) in the gastrointestinal tract has 
been proposed. NO is a membrane-permeable gas 
that serves as a mediator of many physiological 
events (Moncada et a1 1991). It is produced from L- 
arginine by a calcium-dependent NO synthase. 
Numerous studies have implicated NO as a critical 
mediator of mucosal defence, similar to pros- 
taglandins (Whittle et a1 1990). NO, or drugs that 
generate NO (e.g. sodium nitroprusside, glyceryl 
trinitrate) have been shown to reduce the severity 
of gastric mucosal injury in experimental models 
(Whittle et a1 1990; Brown et a1 1993) and some 
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authors have suggested that the gastroprotective 
effect of L-arginine could be through an NO-path- 
way (Kitagawa et a1 1990; Konturek et a1 1993) 
Ibuprofen is a potent NSAID that recently has been 
formulated with equimolar doses of L-arginine in 
order to improve pharmacokinetic parameters 
(higher and more rapid absorption) with quicker 
and more potent analgesic effect. In a previous 
report we found that administration of L-arginine 
before ibuprofen treatment induced significant 
inhibition of gastric lesions (Motilva et a1 1996). 
Thus, we designed this study to confirm the pro- 
tective effect of the ibuprofen and L-arginine for- 
mulation vs ibuprofen alone, and to compare this 
gastroprotection with other traditional therapies 
such as misoprostol (PGE1 analogue), ranitidine (a 
classic antisecretory agent) or roxatidine (a new 
anti-H2 drug). 
Material and Methods 
Animal groups and compounds 
Male Wistar rats (supplied by Animal Services, 
Faculty of Medicine, Seville), 180-250 g, were 
used. The animals were fed a normal laboratory 
diet in a controlled room (temperature 22-24°C 
and humidity at 70-75%). They were placed in 
single cages with wire-net floors to prevent 
coprophagy, and were deprived of food for 18 h 
before the experiments but had free access to water. 
Groups of 9-10 rats were treated with different 
doses of ibuprofen (Sigma Chemical Co., MO), 
ibuprofen and L-arginine (Zambon S.A., Barcelona, 
Spain), ranitidine (Sigma Chemical Co., MO), 
roxatidine (Zambon S.A., Barcelona, Spain) and 
misoprostol (CECOFAR, Seville, Spain). The 
drugs were suspended in distilled water and were 
administered by the intragastric route, in a dose of 
1 m L / l O O  g body weight. Control groups received 
vehicle in comparable volume. Each experiment 
was performed at least twice and results were 
pooled. 
Experimental protocol 
Different groups of animals were treated with 
ibuprofen (0.3, 0.6 and 1-20 mmol kg-') and 
equimolar doses of ibuprofen and L-arginine 
(0.3/0-3, 0.6/0-6 and 1-20/1.20 mmol kg-'). Six 
hours after treatment the animals were killed using 
an overdose of ethyl ether and the stomachs were 
removed and cut along the smaller curvature. The 
gastric lesions were immediately evaluated and the 
following parameters related to damage were 
assessed. Gastric damage (score): 0, absence of 
lesions; 1, haemorrhagic or necrotic mucosa; 2, 
pointed lesions; 3, pointed lesions with lesions 
< 3 mm; 4, mainly lesions > 3 mm. Area of gas- 
tric damage (mm2): the product of ulcer length and 
width was calculated. Mucosal damage (%): 
reduction of damaged area of the different groups 
compared with the respective equimolar dose of 
ibuprofen alone (100%). Ratio lesioned sto- 
machs/total stomachs evaluated. Presence of hae- 
morrhage (score): 0, absence; 1, slight 
haemorrhage; 2, marked haemorrhage. 
The intermediate gastrolesive dose of ibuprofen 
(0.6 mmol kg-') noted in these experiments was 
selected to examine the protective effect of mis- 
oprostol, ranitidine and roxatidine. New groups of 
animals received the following treatments: ibupro- 
fen alone; equimolar dose of ibuprofen and L- 
arginine (0-6/0.6 mmol kg-'); ibuprofen and 
misoprostol (0-6/0.05 x mmol kg-l); ibu- 
profen and ranitidine (0.6/0.05 mmol kg-'); and 
ibuprofen and roxatidine (0-6/0.05 mmol kg- '). 
After the experimental period, the animals were 
killed and the stomachs removed, opened and 
assessed as in the previous experiments. The same 
parameters were evaluated. 
Analysis of results 
Statistical analysis was performed using conven- 
tional methods (arithmetic mean f s.e.). One-way 
analysis of variance was used to test for significant 
differences of means of treatment groups. Multiple 
comparison between means was performed using 
the Mann-Whitney U-test and X2-test at a protec- 
tion level of 0.05. 
Results 
Six hours after dosing, ibuprofen given orally in 
various doses (0.3, 0-6 and 1.20 mmol kg-') pro- 
duced a progressive dose-dependent increase of 
damage to the gastric mucosa (4.12 z t  1.01, 
17.88 f 2.74 and 66.41 f 9.17 mm2, respectively). 
Oral treatment of the animals with equimolar doses 
of L-arginine considerably reduced the gastric 
lesions (0.6 and 1.20 mmol kg-', P < 0.001 
against ibuprofen alone, mm2 and score). The same 
tendency was evaluated with the other parameters, 
degree of haemorrhage and percentage of mucosal 
damage (Table 1). 
Significant decreases in the gastric lesion para- 
meters were found with all the treatments shown in 
Table 2. The most marked reduction of the lesion 
(mm2 and score), as well as haemorrhagic score 
and percentage of mucosal damage, was observed 
with ranitidine, roxatidine and misoprostol 
( P  < 0.001). However, L-arginine treatment also 
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Table 1. The anti-ulcer protection of different doses of L-arginine in the presence of equimolar doses of ibuprofen in rats. 
Treatment Haemorrhage Gastric damage Mucosal Lesioned stomachsf Gastric damage 
(score) (mm2) damage (%) stomachs evaluated (score) 
None 0.00 f 0.00 0.00 f 0.00 0.0 0120 0.00 f 0.00 
Ibuprofen 0.20 f 0.06 4.12f 1.01 100 19/20 2.15f0.20 
Ibuprofen and 0.08 f 0.04 2.47 f 0.68 59.8 19/20 1.95 f 0.15 
(0.3 mmol kg-I) 
L-arginine 
(0.3 mmol kg-I) 
(0.6 mmol kg- I )  
L-arginine 
(0.6 mmol kg-I) 
Ibuprofen 1.03 f 0 . 1 2  17.88 f 2.74 100 19/19 3.21 f0 .10  
Ibuprofen and 0.32 f 0.1 1 * 6.29 f 1.33* 35.2 19/19 2.31f0.11 
Ibuurofen 1.82 f 0.10 66.41 f 9.17 100 19/19 4.0 f 0.01 
(1.20 mmol kg-') 
Ibuprofen and 0.23 f0.09* 17.97 f4.15* 27.1 19/20 2.45 f 0.18* 
L-arginine 
(1.20 mmol kg- I )  
Results are means * s.e. (n = 19 or 20). *P < 0.001, ibuprofen and L-arginine vs ibuprofen alone (Mann-Whitney U-test). 
Table 2. The effects of different treatments in the presence of ibuprofen (0.06 mmol kg-I): L-arginine (0.6 mmol kg-I), 
ranitidine (0.05 mmol kg-'), roxatidine (0.05 mmol kg-') and misoprostol (0.05 x mmol kg-') on parameters of gastric 
damage in rats. 
Treatment Haemorrhage Gastric damage Mucosal Lesioned stomachsf Gastric damage 
(score) (mm2) damage(%) stomachs evaluated (%) (score) 
Ibuprofen alone 1.03 f 0 . 1 2  17.88 f 2.74 100 100 3.21 f 0 . 1 0  + L-Arginine 0.32 * 0.11 * 6.29 f 1.33* 35.2 100 2.31 f0.11* + Misoprostol 0.13 f 0.06* 2.25 * 0.76* 12.6 89.5 1.95 f 0.21 * + Ranitidine 0.10 f 0.05* 1.43 f 0.61 * 8.0 68.41- 1.50 f 0.29* + Roxatidine 0.10 f 0.02* 0.08 f 0.07 0.5 66.7t 1 .OO f 0.25 
Results are means f s.e. (n = 19 or 20). *P < 0,001, treatment groups vs ibuprofen alone, Mann-Whitney U test; t P  < 0.01, 
x2 test. 
induced very marked decreases in all parameters 
evaluated (P  < 0.001). 
Discussion 
There is overwhelming evidence that NO is one of 
the most important mediators of mucosal defence, 
affecting factors such as mucus secretion, mucosal 
blood flow, ulcer repair and the activity of a variety 
of mucosal immunocytes. Endogenous NO has the 
capacity to down-regulate inflammatory responses 
in the gastrointestinal tract (Kubes & Wallace 
1995), and it has been shown to be involved in 
certain types of gastroprotection such as that 
induced by capsaicin, papaverine (Brzozowski et a1 
1993), sucralfate and mild irritants (Konturek et a1 
1994). In this way, the ability of NO to reduce the 
severity of damage induced by NSAIDs has 
recently been exploited in an attempt to produce 
drugs which are not ulcerogenic. By attaching an 
NO-releasing moiety to standard NSAIDs (by 
incorporation of a nitroxybutyl moiety (e.g. flurbi- 
profen, ketoprofen and diclofenac nitroxy-butyl- 
ester), the gastrointestinal toxic effects of these 
compounds was greatly reduced but did not inter- 
fere with their ability to suppress inflammatory 
processes, inhibit prostaglandin synthesis or inhibit 
platelet aggregation (Wallace & Cirino 1994). 
Other recent strategies such as prophylactic therapy 
with the PGEl analogue misoprostol have been 
shown to reduce the incidence of NSAID-induced 
ulcers significantly, but the use of this drug is 
limited by its adverse effects in a considerable 
number of patients. 
However, the effect of L-arginine, the precursor 
of NO, on the gastric mucosal integrity has not 
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been much studied. Our data show that simulta- 
neous treatment with L-arginine significantly 
decreases ibuprofen-induced gastric damage in a 
dose-dependent way. This result is in agreement 
with Kitagawa et a1 (1990) who reported that L- 
arginine given intravenously prevented gastric 
lesions caused by 0-6 M HC1 or water-immersion 
stress. Similar results were obtained by Takeuchi et 
a1 (1993) who found that oral treatment with L- 
arginine exhibits gastric cytoprotection against 
0.6 M HC1-induced lesions in a dose dependent 
manner. This effect was mimicked by the enan- 
tiomer D-arginine and was not affected by previous 
administration of N G-nitro-L-arginine methyl ester 
(L-NAME), a potent inhibitor of NO biosynthesis. 
Thus they suggested that the mucosal protective 
action of L-arginine (p.0.) is unrelated to the NO 
pathway, and its mechanism may appear through 
adaptative cytoprotection mediated by endogenous 
prostaglandins. In contrast, in a previous study, we 
did not observe any protective effect against 
diclofenac-induced gastric injury after D-arginine 
treatment. However, the protection induced by L- 
arginine was maintained after administration of 
L-NAME suggesting, at least in part, the involve- 
ment of NO in the protective mechanism of oral L- 
arginine (Motilva et a1 1997). 
Ferraz et a1 (1994) found that intra-arterial 
administration of L-arginine before the application 
of 20% ethanol produced a dose-dependent 
increase in the extent of damage. L-Arginine sig- 
nificantly reduced gastric blood flow relative to 
controls, and the authors suggested that the increase 
of gastric injury was partly NO dependent and 
partly NO independent. They suggested a para- 
doxical effect of L-arginine on gastric mucosal 
integrity. While small amounts of NO produced 
constitutively by endothelial cells appear to be 
critical for maintenance of mucosal perfusion, large 
amounts of NO can exacerbate mucosal injury, 
probably as a consequence of the cytotoxic prop- 
erties of the NO radical or the peroxynitrite radical 
formed through the interaction of NO with super- 
oxide. 
We conclude that, under our experimental con- 
ditions, intragastric administration of L-arginine 
protects the gastric mucosa against ibuprofen- 
induced injury, and that this protective effect is 
comparable with those of antisecretory agents or 
misoprostol. However the mechanism involved in 
this beneficial action have not been studied. It is 
possible that L-arginine achieves direct cytopro- 
tective effect on mucosal tissue and that this 
property could be related to the NO-pathway, but 
these suppositions require further exploration. 
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